FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue

The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), reported a loss of $41.09 million in the first quarter, half the $80.9 million loss from the same period a year earlier, according to its latest results published on Wednesday. Looking up: Legend Biotech’s revenue tripled year-on-year to $40.8 million in the latest quarter, thanks to milestone payments from a drug collaboration agreement with Janssen Biotech. Take Note: The company’s selling and distribution expenses jumped 59% to $21.3 million during the latest reporting quarter, even though it has yet to generate any…

Read More »

EHang’s Order Book Takes Flight as Cash Pile Glides to Earth

Autonomous air vehicle maker announces major new pre-order from Indonesia and intent to form joint venture in Thailand Key Takeaways: EHang has announced a major new deal to sell 100 of its autonomous air vehicles to an Indonesian buyer, doubling its order book for this year Company is slashing expenses as its cash fell to 237 million yuan at the end of March from 480 million yuan a year earlier By Doug Young A look at the latest earnings report from EHang Holdings Ltd. (HANG.US) appears to show a company…

Read More »